The clinical spectrum of labile hypertension: a management dilemma

Samuel J Mann

doi:10.1111/j.1751-7176.2009.00155.x

The clinical spectrum of labile hypertension: a management dilemma

J Clin Hypertens (Greenwich). 2009 Sep;11(9):491-7. doi: 10.1111/j.1751-7176.2009.00155.x.

Author

Samuel J Mann¹

Affiliation

¹ Division of Nephrology and Hypertension, Department of Medicine, New York Presbyterian Hospital, Weill/Cornell Medical Center, New York, NY 10021, USA. sjmann@med.cornell.edu

Abstract

J Clin Hypertens (Greenwich). 2009;11:491-497. (c)2009 Wiley Periodicals, Inc.Although the management of the labile component of blood pressure elevation is a problem often encountered by clinicians, there is a paucity of information available to guide therapeutic decisions. This review discusses the clinical relevance of blood pressure lability, the limitations of current knowledge, and possible directions for future research and clinical management.

Publication types

Review

MeSH terms

Angiotensin II Type 1 Receptor Blockers / therapeutic use
Angiotensin-Converting Enzyme Inhibitors / therapeutic use
Antihypertensive Agents / therapeutic use
Blood Pressure*
Diuretics / therapeutic use
Evidence-Based Medicine
Humans
Hypertension / diagnosis
Hypertension / physiopathology*
Hypertension / prevention & control
Male

Substances

Angiotensin II Type 1 Receptor Blockers
Angiotensin-Converting Enzyme Inhibitors
Antihypertensive Agents
Diuretics